ADMA Biologics, Inc. (ADMA) News & Corporate Actions | Announcements, Board Meetings, Splits, Bonuses, Rights Issues

{
  "main_header": {
    "sid": 1149602,
    "name": "ADMA Biologics, Inc.",
    "stock_name": "ADMA Biologics, Inc.",
    "full_name": "ADMA Biologics, Inc.",
    "name_url": "stocks-analysis/adma-biologics-inc",
    "exchange": 210,
    "exchangecode": "NAS",
    "country_id": 2,
    "currency": "USD",
    "cmp": "18.81",
    "chg": -0.02,
    "chgp": "-0.11%",
    "dir": -1,
    "prev_price": "18.83",
    "mcapval": "3,918.32",
    "mcap": "Small Cap",
    "scripcode": "",
    "symbol": "",
    "ind_name": "Pharmaceuticals & Biotechnology",
    "ind_code": 2320,
    "indexname": "S&P 500",
    "isin": "US0008991046",
    "curr_date": "Dec 18",
    "curr_time": "",
    "bse_nse_vol": "3.4 M",
    "exc_status": "Active",
    "traded_date": "Dec 18, 2025",
    "traded_date_str": "2025 12 18",
    "score": "",
    "scoreText": "",
    "Live": 0,
    "market_time": 0,
    "is_blur": 1,
    "is_blur_class": "blur-registerF-score-header",
    "is_blur_url": "https://www.marketsmojo.com/mojofeed/register?redirect=/stocks-analysis/adma-biologics-inc-1149602-210&utm_source=Spage_Header_Score",
    "mojoone": {
      "ismore": 0
    }
  },
  "news": {
    "results": [
      {
        "title": "ADMA Biologics Adjusts Valuation Amid Strong Financial Performance and Growth Metrics",
        "link": "https://www.marketsmojo.com/news/stock-recommendation/adma-biologics-upgraded-to-buy-as-valuation-improves-and-financials-strengthen-3640203",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/10/ADMABiologicsIn_mojoScore_3640203.png",
        "date": "2025-10-23 15:42:57",
        "description": "ADMA Biologics, Inc. has recently adjusted its valuation grade, reflecting a more favorable assessment of its financial standing. The company showcases strong metrics, including a P/E ratio of 24, a high ROE of 55.71%, and consistent growth in net sales, maintaining a positive performance over 17 quarters."
      },
      {
        "title": "Is ADMA Biologics, Inc. overvalued or undervalued?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/is-adma-biologics-inc-overvalued-or-undervalued-3637649",
        "imagepath": "",
        "date": "2025-10-21 12:06:27",
        "description": "As of 17 October 2025, the valuation grade for ADMA Biologics, Inc. moved from expensive to fair. The company appears to be fairly valued based on its current metrics. Key ratios include a P/E ratio of 24, a Price to Book Value of 13.18, and an EV to EBITDA of 30.78, which suggest a balanced valuation relative to its earnings and assets.\n\nIn comparison to its peers, ADMA Biologics, Inc. has a P/E ratio of 18.56, while Protagonist Therapeutics, Inc. is considered very expensive with a P/E of 67.18. This indicates that ADMA is positioned more favorably in terms of valuation compared to some competitors. Notably, while ADMA's stock has underperformed against the S&P 500 in the short term, with a year-to-date return of -16.27% compared to the S&P 500's 13.30%, it has significantly outperformed over longer periods, with a 3-year return of 433.83% versus 81.19% for the index...."
      },
      {
        "title": "ADMA Biologics Experiences Revision in Its Stock Evaluation Amid Strong Performance Metrics",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/adma-biologics-changes-valuation-grade-from-expensive-to-fair-amid-stock-fluctuations-3640414",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/10/ADMABiologicsIn_valuationdot_3640414.png",
        "date": "2025-10-20 15:19:02",
        "description": "ADMA Biologics, Inc. has recently adjusted its valuation, showcasing a P/E ratio of 24 and a strong return on capital employed of 40.49%. Compared to peers, it presents a favorable profile, with significant long-term performance, achieving returns of 433.83% and 532.60% over three and five years, respectively."
      },
      {
        "title": "Is ADMA Biologics, Inc. overvalued or undervalued?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/is-adma-biologics-inc-overvalued-or-undervalued-3634518",
        "imagepath": "",
        "date": "2025-10-20 12:23:50",
        "description": "As of 17 October 2025, the valuation grade for ADMA Biologics, Inc. has moved from expensive to fair. The company appears to be fairly valued based on its current metrics. Key ratios include a P/E ratio of 24, an EV to EBITDA of 30.78, and a PEG ratio of 0.03, which suggests potential growth relative to its price.\n\nIn comparison with peers, ADMA Biologics has a fair valuation with a P/E of 18.56, while Protagonist Therapeutics, Inc. is considered very expensive with a P/E of 67.18. The company has also outperformed the S&P 500 significantly over the long term, with a 3-year return of 433.83% compared to the S&P 500's 81.19%, although it has underperformed in the short term...."
      },
      {
        "title": "Is ADMA Biologics, Inc. overvalued or undervalued?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/is-adma-biologics-inc-overvalued-or-undervalued-3632056",
        "imagepath": "",
        "date": "2025-10-19 12:01:24",
        "description": "As of 17 October 2025, the valuation grade for ADMA Biologics, Inc. moved from expensive to fair. The company is currently fairly valued based on its financial metrics. Key ratios include a P/E ratio of 24, a Price to Book Value of 13.18, and an EV to EBITDA of 30.78. In comparison, its peer Protagonist Therapeutics, Inc. is considered very expensive with a P/E ratio of 67.175, while Rayzebio, Inc. does not qualify for comparison due to negative metrics.\n\nDespite recent struggles, with a year-to-date return of -16.27% compared to the S&P 500's 13.30%, ADMA Biologics has shown impressive long-term performance, with a 3-year return of 433.83% versus the S&P 500's 81.19%. This suggests that while the stock may be facing short-term challenges, its valuation appears justified given its historical performance and current metrics...."
      }
    ],
    "total": 12,
    "sid": "1149602",
    "stock_news_url": "https://www.marketsmojo.com/news/adma-biologics-inc-1149602"
  },
  "announcements": "",
  "corporate_actions": {
    "msg": "No corporate action Found"
  }
}

News and Views

ADMA Biologics Adjusts Valuation Amid Strong Financial Performance and Growth Metrics

2025-10-23 15:42:57

ADMA Biologics, Inc. has recently adjusted its valuation grade, reflecting a more favorable assessment of its financial standing. The company showcases strong metrics, including a P/E ratio of 24, a high ROE of 55.71%, and consistent growth in net sales, maintaining a positive performance over 17 quarters.

Is ADMA Biologics, Inc. overvalued or undervalued?

2025-10-21 12:06:27

As of 17 October 2025, the valuation grade for ADMA Biologics, Inc. moved from expensive to fair. The company appears to be fairly valued based on its current metrics. Key ratios include a P/E ratio of 24, a Price to Book Value of 13.18, and an EV to EBITDA of 30.78, which suggest a balanced valuation relative to its earnings and assets. In comparison to its peers, ADMA Biologics, Inc. has a P/E ratio of 18.56, while Protagonist Therapeutics, Inc. is considered very expensive with a P/E of 67.18. This indicates that ADMA is positioned more favorably in terms of valuation compared to some competitors. Notably, while ADMA's stock has underperformed against the S&P 500 in the short term, with a year-to-date return of -16.27% compared to the S&P 500's 13.30%, it has significantly outperformed over longer periods, with a 3-year return of 433.83% versus 81.19% for the index....

ADMA Biologics Experiences Revision in Its Stock Evaluation Amid Strong Performance Metrics

2025-10-20 15:19:02

ADMA Biologics, Inc. has recently adjusted its valuation, showcasing a P/E ratio of 24 and a strong return on capital employed of 40.49%. Compared to peers, it presents a favorable profile, with significant long-term performance, achieving returns of 433.83% and 532.60% over three and five years, respectively.

Is ADMA Biologics, Inc. overvalued or undervalued?

2025-10-20 12:23:50

As of 17 October 2025, the valuation grade for ADMA Biologics, Inc. has moved from expensive to fair. The company appears to be fairly valued based on its current metrics. Key ratios include a P/E ratio of 24, an EV to EBITDA of 30.78, and a PEG ratio of 0.03, which suggests potential growth relative to its price. In comparison with peers, ADMA Biologics has a fair valuation with a P/E of 18.56, while Protagonist Therapeutics, Inc. is considered very expensive with a P/E of 67.18. The company has also outperformed the S&P 500 significantly over the long term, with a 3-year return of 433.83% compared to the S&P 500's 81.19%, although it has underperformed in the short term....

Is ADMA Biologics, Inc. overvalued or undervalued?

2025-10-19 12:01:24

As of 17 October 2025, the valuation grade for ADMA Biologics, Inc. moved from expensive to fair. The company is currently fairly valued based on its financial metrics. Key ratios include a P/E ratio of 24, a Price to Book Value of 13.18, and an EV to EBITDA of 30.78. In comparison, its peer Protagonist Therapeutics, Inc. is considered very expensive with a P/E ratio of 67.175, while Rayzebio, Inc. does not qualify for comparison due to negative metrics. Despite recent struggles, with a year-to-date return of -16.27% compared to the S&P 500's 13.30%, ADMA Biologics has shown impressive long-term performance, with a 3-year return of 433.83% versus the S&P 500's 81.19%. This suggests that while the stock may be facing short-term challenges, its valuation appears justified given its historical performance and current metrics....

View All News